Harrow licenses Canadian rights to five ophthalmic products to Apotex; eligible for milestone payments and royalties

HARROW, INC.

Apotex gets exclusive Canadian rights to VERKAZIA and Cationorm PLUS; will pursue approval for VEVYE, IHEEZO, and ZERVIATE.
Harrow eligible for milestone payments tied to manufacturing, regulatory approval, and commercial milestones plus royalties on net sales.
Apotex is Canada's largest pharmaceutical company, with a track record in eyecare.
Deal covers both prescription (VERKAZIA) and OTC (Cationorm PLUS) products, expanding Harrow's reach into Canada.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.